Abstract
Since 1988 we have treated a first group of 14 patients with recombinant interleukin-2 (rIL-2), which was previously published, and 6 other consecutive patients affected by refractory or relapsed acute myelogenous leukemia (AML) with >5% and < or = 30% bone marrow blasts, but not suitable for further chemotherapy. The rIL-2 schedule consisted of four 5-day high-dose cycles administered by continuous infusion with a 72-hour rest period between each cycle. Patients who achieved a response received a lower dose of subcutaneous rIL-2 maintenance treatment administered for 5 days every month. Following high-dose rIL-2, 11/20 patients (55%) obtained a complete remission (CR). Six remain in persistent CR after a median follow-up time of 50 months (9, 33, 49, 51, 52, 87 months, respectively); the length of remission is the longest in the natural history of the disease for each individual patient. One patient with stable disease at the end of rIL-2 induction is alive and well, with a stable number of blasts in the bone marrow, 18 months later. These 7 patients continue maintenance treatment with subcutaneous rIL-2. Close clinical and laboratory monitoring reveal that side effects are acceptable and no toxic deaths have been recorded. Th...Continue Reading
References
Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·S H LimA H Goldstone
Jun 1, 1991·The Annals of Thoracic Surgery·A BorgeatD Schwander
Apr 1, 1991·British Journal of Haematology·R FoaF Mandelli
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S AmadoriF Mandelli
Apr 9, 1987·The New England Journal of Medicine·S A RosenbergJ T Rubin
Apr 9, 1987·The New England Journal of Medicine·W H WestR K Oldham
Jan 1, 1987·Leukemia Research·E LotzováR B Herberman
Dec 5, 1985·The New England Journal of Medicine·S A RosenbergJ T Vetto
Jan 1, 1993·The Journal of Clinical Investigation·M A CaligiuriR J Soiffer
Apr 1, 1995·Leukemia Research·R Foa
Feb 1, 1995·Leukemia Research·B JahnP S Mitrou
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R Foa
Jan 1, 1993·Acta Haematologica·A SchomburgJ Atzpodien
Jul 1, 1993·Stem Cells·F MandelliG Meloni
Dec 11, 1987·Health Progress·P McMillen
Jan 1, 1990·Leukemia & Lymphoma·R FoàF Mandelli
Citations
Apr 8, 1999·Cancer·J E CortesE H Estey
Feb 25, 2006·Leukemia·F Ravandi
Oct 16, 1999·British Journal of Haematology·D K Webb
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria R BaerRichard A Larson
May 6, 2014·Current Treatment Options in Oncology·Peter H Wiernik
Apr 24, 2002·Clinical Lymphoma·Chadi Nabhan, Martin S Tallman
Apr 25, 2009·British Journal of Haematology·Wendy IngramFarzin Farzaneh
Apr 18, 2006·Seminars in Hematology·Sherif S Farag, Michael A Caligiuri
May 18, 2001·Best Practice & Research. Clinical Haematology·G F TorelliR Foà
Mar 30, 2007·Mediators of Inflammation·Klabusay MartinTesarova Eva
Oct 3, 2002·Leukemia·G MeloniF Mandelli
Aug 18, 2001·Bone Marrow Transplantation·S CesaroUNKNOWN Italian Pediatric Group for Bone Marrow Transplantation
Jan 28, 2017·Case Reports in Hematology·Pankit VachhaniEunice S Wang
Mar 29, 2018·Expert Review of Hematology·Mansour Alfayez, Gautam Borthakur
Apr 9, 2019·JCO Precision Oncology·Mansour AlfayezCourtney D DiNardo